BioSpace News Archive

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and B. Braun Medical Inc., a global market leader1 in regional anesthesia and pain management, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Onvision®, a breakthrough ultrasound guidance solution for real-time needle tip tracking.

New Foundation grant to fund innovative projects, national convenings and education programs that will enhance the skills of all health care providers and improve the experience of patients

Pediatric clinical staff and those in their care will soon benefit from a new relationship announced between Medline and Texas Children’s Hospital, a U.S. News & World Report Best Children’s Hospital Honor Roll organization.

Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced the Company will host a webinar with University of Louisville School of Medicine to discuss smart glasses usage in healthcare.

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will present at the LD Micro 500 Virtual Conference Tuesday, September 01, 2020 3:00 PM ET. A live webcast of the presentation will be available to the public at https://www.webcaster4.com/Webcast/Page/2019/36399 . The webcast will be archived for 90 days following the liv

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the closing of its upsized initial public offering of 9,987,520 common shares, including the exercise in full by the underwriters of their option to purchase up to 1,302,720

ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund. Additional investors participating in the financing include Andera Partners, Brace Pharma Capital, Green Sands E